Document is current
Any future updates will be listed below
-
Authors
Martín, Fernando https://orcid.org/0000-0002-3496-9093
Alcon, Clara https://orcid.org/0000-0003-3243-9440
Marín, Elba
Morales-Sánchez, Paula https://orcid.org/0000-0002-9563-668X
Manzano-Muñoz, Albert https://orcid.org/0000-0003-4039-7391
Díaz, Sherley
García, Mireia
Samitier, Josep https://orcid.org/0000-0002-1140-3679
Lu, Albert
Villanueva, Alberto https://orcid.org/0000-0001-5164-0006
Reguart, Noemí
Teixido, Cristina https://orcid.org/0000-0002-7226-6567
Montero, Joan https://orcid.org/0000-0002-9192-4836
- License Information
-
More Information
Article History
Received: 21 February 2024
Revised: 29 January 2025
Accepted: 11 March 2025
First Online: 20 March 2025
Competing interests
: JM is co-inventor of dynamic BH3 profiling (patented by Dana-Faber Cancer Institute) and has received royalties, was a paid consultant for Oncoheroes Biosciences and Vivid Biosciences, is an unpaid board member for The Society for Functional Precision Medicine, and he is currently collaborating with AstraZeneca. NR reports advisory board activities for Amgen Inc., AstraZeneca, Bayer, Janssen, MSD, Roche, Novartis, Sanofi and Takeda; research funding from MSD, IIT, Pfizer, and Novartis; speaker’s bureau activities for Amgen Inc., Sanofi, Roche, AstraZeneca, Novartis, Bristol-Myers Squibb, and MSD; and membership on a board or advisory committee in MSD. CT has received research funding from Novartis and consulting or advisory and/or speakers bureau fees from Diaceutics, Pfizer, Novartis, AstraZeneca, Takeda, Roche, Bristol-Myers Squibb, Merck Sharp & Dohme. No potential conflicts of interest were disclosed by the other authors.
: Patient samples were retrospectively included in our study with prior fully informed patient consent and approval from the Local Ethical Committee (HCB/2019/0995 V.4 11/12/2019). The study was conducted in accordance with the principles of the Declaration of Helsinki.
